The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Flagged first, then by citations
5 of the 371 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 301–400 of 1,278
Huang, Y., Zhang, Y., Wu, K., Tan, X., Lan, T., & Wang, G. (2024) · Molecules · doi:10.3390/molecules29112663 · Cited by 15
The emerging role of alternatively activated macrophages to treat acute liver injury
Humphries, C., Addison, M., Dear, J. W., & Forbes, S. J. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03892-2 · Cited by 15
Jiang, Y., Li, R., Li, X., & Zhang, N. (2024) · Current Oncology · doi:10.3390/curroncol31110525 · Cited by 15
Xiao, J., Huang, D., Wang, F., Gan, L., Zhang, W., Zhang, F., Tang, J., Shen, Z., Jiang, M., Egbobe, J. O., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115102 · Cited by 15
Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
Shao, Q.-H., Mao, X., Zhou, Z., Huai, C., & Li, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.735260 · Cited by 15
She, Y., Huang, Q., Ye, Z., Hu, Y., Wu, M., Qin, K., Wei, A., Yang, X., Liu, Y., Zhang, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714287 · Cited by 15
Review article: clinical assessment of suspected drug‐induced liver injury and its management
Vuppalanchi, R., & Ghabril, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17246 · Cited by 15
Meunier, L., & Larrey, D. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010852 · Cited by 16
Self-citationDrug-induced liver injury: An overview and update
Wang, Y., & Xie, W. (2023) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2022.11.005 · Cited by 15
Yoo, H., Ji, S. C., Cho, J., Kim, S., Yoon, J. G., Lee, M. G., Yu, K., Jang, I., & Oh, J. (2020) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000423 · Cited by 15
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2020) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.07.009 · Cited by 15
Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications
Kwon, S., & Judson, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051250 · Cited by 14
Levy, D. M., Arush, O. B., Carmi, L., Juven‐Wetzler, A., & Zohar, J. (2024) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2024.152486 · Cited by 15
Román-Sagüillo, S., Castro, R. Q., Juárez‐Fernández, M., Soluyanova, P., Stephens, C. M., Robles‐Díaz, M., Jorquera, F., González‐Gallego, J., Martínez‐Flórez, S., García‐Mediavilla, M. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136863 · Cited by 14
Engel, B., Diestelhorst, J., Hupa‐Breier, K. L., Kirchner, T., Henjes, N., Loges, S., Yüksel, M., Jańczyk, W., Lalanne, C., Zachou, K., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10695-1 · Cited by 14
Natural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models
Devarbhavi, H. C., & Andrade, R. J. (2025) · Liver International · doi:10.1111/liv.70138 · Cited by 14
Self-citationVitale, G., Lamberti, G., Comito, F., Nunno, V. D., Massari, F., Morelli, M. C., Ardizzoni, A., & Gelsomino, F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762562 · Cited by 14
Rituximab-induced autoimmune hepatitis: A case study and literature review
Galiatsatos, P., Assouline, S. E., Gologan, A., & Hilzenrat, N. (2020) · Canadian Liver Journal · doi:10.3138/canlivj-2020-0009 · Cited by 14
Berman, E., Noyman, I., Medvedovsky, M., Ekstein, D., & Eyal, S. (2021) · Epilepsia · doi:10.1111/epi.17147 · Cited by 14
Tzadok, R., Levy, S., Aouizerate, J., & Shibolet, O. (2022) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2022/5090200 · Cited by 14
Zekić, T., Benić, M. S., & Radić, M. (2022) · Rheumatology International · doi:10.1007/s00296-022-05143-y · Cited by 14
Fontana, R. J., Engle, R. E., Hayashi, P. H., Gu, J., Kleiner, D. E., Nguyen, H. V., Barnhart, H. X., Hoofnagle, J. H., & Farci, P. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001869 · Cited by 14
The association of chiral characteristic with drug withdrawal due to safety: A comparative analysis
Aydın, V., Bahar, A., Vızdıklar, C., & Akıcı, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15486 · Cited by 14
Alanine aminotransferase assay biosensor platform using silicon nanowire field effect transistors
Muratore, K. A., Zhou, D., Du, J., Chlystek, J. S., Motesadi, K., Larsen, E. K., Molgora, B. M., Lee, T. C., Pamarti, S., Erramilli, S., et al. (2023) · Communications Engineering · doi:10.1038/s44172-023-00057-4 · Cited by 14
Dong, K., Sun, Y., Gao, X., Wang, J., Wu, X., & Guo, C. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113656 · Cited by 14
Disulfiram-Induced Acute Liver Injury
Ramer, L., Tihy, M., Goossens, N., Frossard, J., Rubbia‐Brandt, L., & Spahr, L. (2020) · Case Reports in Hepatology · doi:10.1155/2020/8835647 · Cited by 14
Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment
Zhang, R., Wang, Q., & Yang, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00368 · Cited by 14
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yu, Y., Sun, J., Cai, J., Chen, M., Dai, C., Wen, T., Xia, J., Ying, M., Zhang, Z., Zhang, X., et al. (2024) · Liver Cancer · doi:10.1159/000541622 · Cited by 13
Life-threatening immune-related adverse events in the intensive care unit: a narrative review
Pichon, S., Zebian, G., Bureau, C., Levy, C., Lacombe, C., Desmedt, E., Wils, P., Merlen, E., Lionet, A., Terriou, L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08155-x · Cited by 13
Palmer, M., Kleiner, D. E., Goodman, Z. D., Brunt, E. M., Avigan, M., Regev, A., Hayashi, P. H., Lewis, J. H., Mehta, R., Harrison, S. A., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17762 · Cited by 13
Niu, H., Solís‐Muñoz, P., García‐Cortés, M., Sanabria‐Cabrera, J., Robles‐Díaz, M., Romero-Flores, R., Bonilla‐Toyos, E., Ortega‐Alonso, A., Pinazo-Bandera, J. M., Cabello, M. R., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107030 · Cited by 13
Self-citationProspective Application of Tannic Acid in Acetaminophen (APAP)-Induced Acute Liver Failure
Lin, Y., Lin, Y.-C., & Hou, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010317 · Cited by 13
Recent advances in the diagnosis of drug-induced liver injury
Ahmed, T., & Ahmad, J. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i2.186 · Cited by 13
Kawano, M., Yano, Y., Yamamoto, A., Yasutomi, E., Inoue, Y., Kitadai, J., Yoshida, R., Matsuura, T., Shiomi, Y., Ueda, Y., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14080815 · Cited by 13
Drug-induced liver injury in children: A nationwide cohort study from China
Lai, R., Li, X., Zhang, J., Chen, J., Yang, C., Xie, W., Yu, Y., Guo, X., Zhang, X., Lu, G., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101102 · Cited by 13
Fu, H., Zhao, S., Song, S., & Xie, Q. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1432049 · Cited by 13
Zhang, X., Geng, Q., Lin, L., Zhang, L., Shi, C., Liu, B., Yan, L., Cao, Z., Li, L., Li, L., et al. (2024) · Toxicology · doi:10.1016/j.tox.2024.153900 · Cited by 13
Role of liver biopsy in the management of idiosyncratic DILI
Kleiner, D. E. (2024) · Liver International · doi:10.1111/liv.16097 · Cited by 13
Mura, V. L., Colombo, M., Foster, G. R., Angeli, P., Miesbach, W., Klamroth, R., Pierce, G. F., O’Mahony, B., Lim, M. Y., Hernández–Gea, V., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.08.018 · Cited by 13
Bessone, F., Hillotte, G. L., Tamagnone, N., Arnedillo, D., & Roma, M. G. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00325 · Cited by 13
Llovet, L., Gratacós‐Ginès, J., Ortíz, O., Rodríguez‐Tajes, S., Lens, S., Reverter, E., Ruiz‐Ortiz, E., Costa, J. M., Viñas, O., Forns, X., et al. (2019) · Liver International · doi:10.1111/liv.14332 · Cited by 13
Hepatotoxicity of FDA-approved small molecule kinase inhibitors
Jiang, H., Jin, Y., Yan, H., Xu, Z., Yang, B., He, Q., & Luo, P. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867104 · Cited by 13
Akimoto, H., Nagashima, T., Minagawa, K., Hayakawa, T., Takahashi, Y., & Asai, S. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00407 · Cited by 13
Huang, Y.-S., Tseng, S.-Y., Chen, W.-W., Chang, T.-T., Peng, C.-Y., Lo, G.-H., Hsu, C.-W., Hu, C.-T., & Huang, Y.-H. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000648 · Cited by 13
Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI
Stern, S., Wang, H., & Sadrieh, N. K. (2023) · Cells · doi:10.3390/cells12111476 · Cited by 13
Pelchen–Matthews, A., Larsen, J. F., Shepherd, L. C., Begovać, J., Pedersen, K. B., Wit, S. D., Horban, A., Jabłonowska, E., Johnson, M. A., Khromova, I., et al. (2021) · HIV Research & Clinical Practice · doi:10.1080/25787489.2021.2003132 · Cited by 13
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
Yue, M., Li, C., & Li, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111799 · Cited by 12
Sisi, M., Vitale, G., Fusaroli, M., Riefolo, M., Giunchi, V., D’Errico, A., Ardizzoni, A., Raschi, E., & Gelsomino, F. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100563 · Cited by 12
Protective effects and mechanism of Sangyu granule on acetaminophen-induced liver injury in mice
Xiao, K., Li, H., Li, Y., Zhan, B., Fang, X., Zhao, B., Zhang, X., Wu, Y., Wang, F., & Jia, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118282 · Cited by 12
Jiang, A., Wei, C., Zhu, W., Wu, F., & Wu, B. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241244585 · Cited by 12
Bu, W., Wang, C., Wu, Y. K., Zhang, P., Zhang, N., Han, Y., Xu, X., Li, S., & Cai, Y. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10773-1 · Cited by 12
Dong, Y., Zhang, Z., Zhi, Y., Li, X., Guo, T., He, L., Zhao, S., Yang, X., Tang, J. T., Zhong, W., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101579 · Cited by 12
Zhu, W., Wang, L., Zhao, X., Wang, T., Shi, X., Ou, X., Wang, Y. C., Wang, X., Duan, W., Wang, Q., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13435 · Cited by 12
Singh, A. K., Verma, S., Kumar, P. M., Soni, H., Sharma, S., Sharma, S., Patil, A., & Sharma, V. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1835468 · Cited by 12
Smith, M. K., Chan, Y., Suo, A. E., Shaheen, A. A., Congly, S. E., Tandon, P., Bhanji, R. A., Wells, M. M., Cheng, T., & Ma, C. (2021) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwab019 · Cited by 12
Nakafero, G., Grainge, M. J., Card, T. R., Taal, M. W., Aithal, G. P., Zhang, W., Doherty, M., Fox, C. P., Mallen, C. D., & Abhishek, A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab790 · Cited by 12
Self-citationHepatotoxicity of metronidazole in Cockayne syndrome: A clinical report
Hunaut, T., Boulagnon‐Rombi, C., Thorn, H., Doco‐Fenzy, M., & Thiéfin, G. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104388 · Cited by 12
Orzeł-Gajowik, K., Milewski, K., & Zielińska, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010224 · Cited by 12
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology
Lewis, J. H., Khaldoyanidi, S. K., Britten, C. D., Wei, A. H., & Subklewe, M. S. (2022) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000932 · Cited by 12
Huang, D., Peng, J., Lin, L., Chen, Y., Zhu, Z., Cai, Q., Deng, Y., & Chen, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00077 · Cited by 12
Yang, Y., Liu, M., Zhao, T., Chen, Q., Yang, Y., Wang, S., Zhang, J., Deng, G., Sun, K., Nan, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1039558 · Cited by 12
Yang, H., Han, J. W., Lee, J. J., Lee, A., Cho, S. W., Rho, P. R., Kang, M., Jang, J. W., Jung, E. S., Choi, J. Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138112 · Cited by 12
Human Liver Organoid Models for Assessment of Drug Toxicity at the Preclinical Stage
Karabicici, M., Akbari, S., Ertem, Ö., Gümüştekin, M., & Erdal, E. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230411100121 · Cited by 12
Li, M., Wong, D., Sack, J., Vogel, A. S., Hodi, F. S., Fong, L. H., Lai, J. C., Grover, S., & Zucker, S. D. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7013 · Cited by 12
Aripiprazole reduces liver cell division
Marolt, T. P., Kramar, B., Rozman, K. B., Šuput, D., & Milisav, I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240754 · Cited by 12
Potměšil, P., & Szotkowská, R. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320964152 · Cited by 12
Maermaer, T., Li, X., Yin, Y., Chen, W., Wu, D., Mao, Z., Mamuerjiang, J., Mao, Y., & Shen, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.657805 · Cited by 12
Clinical Characteristics of COVID-19 in Patients With Liver Injury
Chen, F., & Zhou, B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.043 · Cited by 12
Kwak, J. Y., Kim, H.-G., Han, J. H., Jeon, H., Cha, R. R., & Lee, S. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000149 · Cited by 11
Zeng, G., Eslick, G. D., & Weltman, M. (2023) · iLiver · doi:10.1016/j.iliver.2023.05.002 · Cited by 11
Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics
Chiang, Y., Cheng, C., Chuang, P.-J., Chen, Y., Chen, Y.-J., Kuo, C., Lin, S., & Chang, L. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107028 · Cited by 11
Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet
Lucena, M., Paz, M. V., Alvarez-Alvarez, I., Aithal, G. P., Björnsson, E. S., Cakan‐Akdogan, G., Cubero, F. J., Esteves, F., Falcón‐Pérez, J. M., Fromenty, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107046 · Cited by 11
Self-citationJiang, Y., Lv, M., Jin, Z., Wu, Y., Li, X., & Zhang, N. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16184 · Cited by 11
Miyoshi, Y., Shigetsura, Y., Hira, D., Maki, T., Kawashima, H., Sugita, N., Sugawara, N., Kitada, N., Hirai, M., Kawata, M., et al. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00397-z · Cited by 11
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives
Yu, Z., Li, W., Tian, C., Cao, Y., & Zhang, C. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03950-9 · Cited by 11
Taylor, K., Ram, R., Ewart, L. C., Goldring, C. E., Russomanno, G., Aithal, G. P., Kostrzewski, T. M., Bauch, C., Wilkinson, J. M., Modi, S., et al. (2025) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1536756 · Cited by 11
Self-citationSemwal, P., Saini, M. K., & Sarma, M. S. (2025) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v14.i2.101875 · Cited by 11
Unmet needs in autoimmune liver diseases
Kolev, M., Kremer, A. E., Sokollik, C., Gershwin, M. E., Beretta‐Piccoli, B. T., Andrade, R. J., Bobzin, C., de Boer, Y. S., de Martin, E., Deganello, A., et al. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102565 · Cited by 11
Self-citationHo, C., Chen, C., Chang, C., Lee, M., Wang, J., Hu, R., & Lee, P. (2021) · Biomedicines · doi:10.3390/biomedicines9080891 · Cited by 11
Hung, H.-Y., Hung, W.-L., Shih, C., & Chen, C. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2012589 · Cited by 11
Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection
Karlafti, E., Paramythiotis, D., Pantazi, K., Georgakopoulou, V., Kaiafa, G. D., Papalexis, P., Protopapas, A. A., Ztriva, E., Fyntanidou, V., & Savopoulos, C. G. (2022) · Medicina · doi:10.3390/medicina58121848 · Cited by 11
Fu, H., Shen, Z., Lai, R., Zhou, T., Huang, Y., Zhao, S., Mo, R., Cai, M., Jiang, S., Wang, J., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10539-4 · Cited by 11
Xiao, G., Liu, Y., Chen, Y., He, Z., Wen, Y., & Hu, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134254 · Cited by 11
Grove, J. I., Stephens, C. M., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A. L., Bjornsson, E. S., Stirnimann, G., Daly, A. K., Hackl, M., et al. (2023) · Diagnostic and Prognostic Research · doi:10.1186/s41512-023-00155-z · Cited by 11
Self-citationImmune Checkpoint Inhibitor-Induced Liver Injury
Gudd, C. L. C., Sheth, R., Thursz, M. R., Triantafyllou, E., & Possamai, L. A. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1776761 · Cited by 11
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
Yoon, J. G., Jang, D. G., Cho, S.-G., Lee, C., Noh, S. H., Seo, S. K., Yu, J. W., Chung, H. W., Han, K., Kwon, S. S., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01172-8 · Cited by 11
Pinazo-Bandera, J. M., Niu, H., Alvarez-Alvarez, I., Medina‐Cáliz, I., Campo‐Herrera, E. D., Ortega‐Alonso, A., Robles‐Díaz, M., Hernández, N. G. M., Paraná, R., Nunes, V., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107183 · Cited by 11
Self-citationThe Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study
Shi, R., Yang, F., Wu, H., & Liu, Y. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s460338 · Cited by 11
A possible increase in liver enzymes due to amlodipine: A case report
Varghese, G., Madi, L., Ghannam, M., & Saad, R. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20917822 · Cited by 11
Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians
Houron, C., Danielou, M., Mir, O., Fromenty, B., Perlemuter, G., & Voican, C. S. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103127 · Cited by 11
Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond
Gu, R., Liang, A., Liao, G., To, I., Shehu, A. I., & Ma, X. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000457 · Cited by 11
Andújar-Vera, F., Alés-Palmer, M. L., Muñoz-de-Rueda, P., Iglesias-Baena, I., & Ocete-Hita, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713562 · Cited by 10
Drug-induced liver injury: diagnosis of exclusion
Maev, I. V., & Te, P. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.08.202329 · Cited by 10
Zhao, J.-W., Zhao, W., Zhao, M., & Lu, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1499697 · Cited by 10
Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort
Lou, Y., Wang, Y., Liu, J., Wang, Y., Wang, J., Ma, S., Yang, Z., Li, J., & Qiu, Y. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-25 · Cited by 10
Case report text-mining and the risk of mistaking reporting trends for clinical history
Rahman, H. A., & Akram, U. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-7482 · Cited by 10
Vedolizumab-Induced Liver Injury
Mascarenhas, M., Ribeiro, T., Dias, E., Lopes, J., Cardoso, H., & Macedo, G. (2020) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000511644 · Cited by 10
Huang, S., Yang, J., Fu, F., Wang, C., Guo, X., He, B., Xiao, D., Cai, H., & Liu, M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0080 · Cited by 10
El‐Mokhtar, M. A., Ramadan, H. K., Thabet, M. M., Abd‐Elkader, A. S., Fouad, M., Sallam, M. M., Elgohary, E. A., El‐Hafeez, A. A. A., Mohamed, M. E., & Sayed, I. M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.737486 · Cited by 10
Role of immune dysfunction in drug induced liver injury
Girish, C., & Sanjay, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1677 · Cited by 10
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
